ABUS
Arbutus Biopharma Corporation
Biotechnology · Healthcare · United States
4.58
close · 2026-08-13
value
85
cheaper than peers85
quality
100
stronger fundamentals100
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.73× | 83 |
| EV to EBITDA | 5.36× | 81 |
| price to book | 3.47× | 66 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 94.4% | 99 |
| revenue growth | 10054.5% | 97 |
| return on equity | 94.7% | 96 |
| debt to equity | 1.5% | 88 |
4 of 4 measures available
Facts
| market cap | $906M |
| free cash flow | -$90.4M |
| employees | 19 |
| first trade | 2007-07-26 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-13 |